What Is MASLD (NAFLD)? The Most Common Liver Disease Explained

Roughly one in four adults is estimated to have it, most have no symptoms, and most have never been diagnosed. This is a plain-language explainer of what MASLD (the condition formerly called NAFLD) actually is, what raises the risk, and how doctors find it — written as general education, not as medical advice.

These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before use.

If you’ve had bloodwork showing elevated liver enzymes and a doctor mentioned “fatty liver,” or you have metabolic risk factors (extra weight around the midsection, high triglycerides, type 2 diabetes, insulin resistance), the information below is relevant context to bring to that conversation. It is not a substitute for a diagnosis.

The Name Just Changed — Here’s Why

If you’ve been researching this topic, you may have seen both NAFLD and MASLD used for the same thing. They refer to the same condition; the terminology changed in 2023.

NAFLD — Non-Alcoholic Fatty Liver Disease — was the standard term from the 1980s through 2022. Defining the disease by what it isn’t (“non-alcoholic”) caused problems: it described the condition by exclusion, carried a mild stigma, and obscured the actual driver — metabolic dysfunction.

MASLD — Metabolic-Associated Steatotic Liver Disease — was adopted by a multi-society hepatology consensus published in 2023 (a process led through journals including Hepatology and the Journal of Hepatology). “Steatotic” means fat-accumulating; “metabolic-associated” points at the underlying contributors — insulin resistance, elevated triglycerides, high blood sugar, abdominal obesity.

When you see “NAFLD” in older articles and studies, read it as the same condition now called MASLD. The biology didn’t change — the name did.

Prevalence: This Is Not a Rare Condition

Estimates vary by population and by how the condition is measured, but the broad picture is consistent across the literature:

Global: roughly a quarter to a third of adults worldwide, per large meta-analyses.
North America: commonly estimated in the ~24–32% range, higher among people with obesity or type 2 diabetes.
Canada: general-population estimates broadly fall in the 20–30% range.

For perspective, that makes MASLD more common than type 2 diabetes, and far more common than most people assume when they picture “liver disease.” Its rising prevalence over recent decades has tracked alongside increases in obesity and metabolic syndrome, and it is now widely described as the most common chronic liver condition in Western countries.

These figures are estimates from population studies, not a personal diagnosis. Only a clinician can determine whether they apply to you.

You Don’t Have to Drink to Have MASLD

The most important thing to understand: by definition, MASLD is not caused by alcohol. The diagnostic criteria require that significant alcohol consumption is absent (though mild-to-moderate drinking can coexist with it). The contributors are metabolic:

Insulin resistance / type 2 diabetes — consistently described as the strongest associated factor.
Central (abdominal) obesity — visceral fat is strongly linked to fat accumulation in the liver.
Elevated blood triglycerides — correlate with hepatic steatosis.
Metabolic syndrome — the cluster of central obesity, elevated blood pressure, high blood sugar, high triglycerides, and low HDL. MASLD is very common in people who meet these criteria.
Diet — high intake of refined carbohydrates and fructose (especially from sweetened beverages) is implicated in the research literature.
Sedentary lifestyle — physical inactivity is independently associated with MASLD.
Genetics — variants in genes such as PNPLA3 and TM6SF2 are associated with increased risk and severity.

“Lean MASLD.” The condition is also found in a meaningful share of people with a normal BMI — a pattern sometimes called “lean MASLD,” reported more often in people of Asian ancestry. A healthy weight does not, by itself, rule it out.

The Spectrum: From Simple Steatosis to Cirrhosis

MASLD is a spectrum, not a single fixed state. Most people who have it remain at the mildest stage; a minority progress, and where progression occurs the downstream consequences can be serious.

Stage 1 — Hepatic Steatosis (simple fatty liver). Fat accumulates in liver cells (generally defined as fat in more than 5% of them). Typically no symptoms; enzymes may be normal or mildly elevated. The literature describes this earliest stage as often improving with the lifestyle changes a clinician may recommend.

Stage 2 — MASH (Metabolic-Associated Steatohepatitis). Previously called NASH. Inflammation appears alongside the fat. This is the stage at which scarring (fibrosis) can begin and the risk of serious outcomes rises.

Stage 3 — Fibrosis. Repeated injury triggers scarring. Earlier fibrosis can be partly reversible; more extensive scarring is harder to reverse. Often still without distinctive symptoms.

Stage 4 — Cirrhosis. Extensive, largely irreversible scarring that distorts the liver’s architecture and can lead to complications such as portal hypertension. Management at this stage focuses on preventing complications.

Advanced complications. On a background of cirrhosis, the risk of liver cancer (hepatocellular carcinoma) increases. MASLD-related liver disease is among the faster-growing reasons for liver transplantation in Western countries.

This staging is general medical education. Where any individual sits on this spectrum is something only a clinician can assess.

Why Most People Don’t Know They Have It

MASLD is often called a “silent” condition because the early-to-middle stages can span years with essentially no symptoms — the liver has substantial functional reserve. When symptoms do eventually appear, they tend to be late and non-specific (fatigue, right-upper-quadrant discomfort, or the complications of advanced disease).

How it’s typically found:

Routine bloodwork showing elevated liver enzymes (ALT, GGT, AST) — the most common route to discovery. Note that normal enzymes don’t rule it out; a substantial share of people with simple steatosis have normal enzyme levels.
Liver ultrasound — can detect fat in the liver but may miss mild cases and can’t stage fibrosis.
FibroScan (transient elastography) — a non-invasive measure of liver stiffness used to estimate fibrosis.
Liver biopsy — the most definitive tool, but invasive and reserved for cases where advanced disease is suspected.

If your bloodwork has flagged liver enzymes, the next step is a conversation with your doctor about which of these, if any, is appropriate — not self-diagnosis.

→ Liver enzymes explained: ALT, GGT, and AST normal ranges

What Medical Science Says About Management

Management of MASLD is a medical matter directed by a clinician. The general picture in the published literature:

Lifestyle is the foundation. Across guidelines, the interventions with the strongest evidence base for early-stage MASLD are gradual weight loss (where appropriate), increased physical activity, and dietary changes that reduce refined carbohydrate and added-sugar intake. Studies report that even modest, sustained weight loss is associated with reductions in liver fat.

Prescription medicine is evolving. As of 2026, treatment of MASLD/MASH with medication is a physician’s decision based on stage and individual factors. The first MASH-specific drug, resmetirom, received FDA approval in 2024 for certain patients with fibrosis, and several other agents are in late-stage trials. GLP-1 medications studied primarily for diabetes and obesity have also shown liver-related signals as secondary findings. None of this is something to self-prescribe.

On supplements — a neutral note. No dietary supplement is a treatment for liver disease, and supplements are not a substitute for medical care. For context only: a small 12-month randomized trial published in early 2026 gave MASLD patients 300 mg/day of dihydromyricetin (DHM) alongside vitamins C and E and choline, and reported improvements in liver-enzyme markers and liver stiffness. It is a single small study, the DHM was not given on its own, and it is not evidence that any supplement treats, prevents, or reverses liver disease. Anyone with a diagnosis should make decisions about supplements with their doctor, not based on a single trial.

→ Liver health supplements: what the evidence does and doesn’t show

Practical Takeaway

If you have any of these — elevated liver enzymes on bloodwork, central obesity, type 2 diabetes, metabolic syndrome, high triglycerides, or a family history of liver disease — MASLD is a reasonable topic to raise with your doctor. Inexpensive, non-invasive starting points (an ALT/GGT blood panel and an ultrasound) can provide meaningful information.

If you’ve already been told you have “fatty liver” or elevated enzymes, the single most evidence-backed levers in the literature are the lifestyle ones — and the right plan for you is the one your clinician helps you build. This article is background reading for that conversation, not a replacement for it.

Frequently Asked Questions

Is MASLD the same as NAFLD? Yes. They name the same condition. “MASLD” (Metabolic-Associated Steatotic Liver Disease) is the term adopted by a 2023 hepatology consensus to replace “NAFLD” (Non-Alcoholic Fatty Liver Disease). Older studies use NAFLD; the biology is identical.

Can you have fatty liver without drinking? By definition, yes — MASLD is the form of fatty liver that is not driven by alcohol. Its main associations are metabolic: insulin resistance, central obesity, high triglycerides, and type 2 diabetes.

How do you know if you have it? You generally don’t from symptoms alone, because early MASLD is usually silent. It’s most often picked up incidentally through elevated liver enzymes on routine bloodwork, then assessed further with imaging such as ultrasound or FibroScan. Diagnosis is a clinician’s call.

Is MASLD reversible? The literature describes the earliest stage as frequently improving with the lifestyle changes a doctor may recommend, while advanced scarring (cirrhosis) is largely not reversible. Where any individual sits, and what’s realistic, is something to determine with a physician.

Does any supplement treat MASLD? No supplement is a treatment for liver disease, and none should be used as a substitute for medical care. Some compounds have been studied in small trials, but a single small study is not evidence of treatment. If you have a diagnosis, decisions about supplements belong in a conversation with your doctor.

Reviewed for accuracy against the cited primary literature. Hovenia is a liver-health supplement company; our product supports healthy liver function and is not intended to diagnose, treat, cure, or prevent any disease. This statement has not been evaluated by the FDA or Health Canada.

The brand behind this: Hovenia is single-ingredient pure DHM — 1,000 mg per serving, $1/serving, for the nights you drink. Join the waitlist → · See the product →